Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Single Dose Pilot Study to Assess Safety, Tolerability and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder

Trial Profile

Open-Label Single Dose Pilot Study to Assess Safety, Tolerability and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risperidone (Primary) ; Risperidone
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Lyndra

Most Recent Events

  • 11 Jun 2020 According to a Lyndra media release, enrollment and dosing in this trial has been completed.
  • 11 Jun 2020 Status changed from not yet recruiting to active, no longer recruiting, according to a Lyndra media release.
  • 14 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top